Status:

COMPLETED

Evaluation of the Pharmacokinetics of NRL972 Following Pre-Administration of Rifampicin and Cyclosporine

Lead Sponsor:

Norgine

Conditions:

Pharmacokinetics

Eligibility:

All Genders

21-40 years

Phase:

PHASE1

Brief Summary

A study in healthy volunteers to determine whether different drugs metabolised by the liver have any effects on how NRL972 is processed within the body.

Eligibility Criteria

Inclusion

  • Males or females (females of non-childbearing potential or of childbearing potential while taking medically appropriate contraception)
  • Caucasian
  • Age: 21 - 40 years
  • BW 50 - 100 kg
  • BMI 20 - 26 kg.m-2
  • healthy based on the pre-study examination
  • willing and able to provide informed consent

Exclusion

  • General - all subjects
  • Previous participation in the trial
  • Participant in any other trial during the last 90 days
  • Donation of blood during the last 60 days or a history of blood loss exceeding 300 mL within the last 3 months
  • History of any clinically relevant allergy (including hypersensitivity to the trial medications)
  • Presence of acute or chronic infection
  • Presence or history of any relevant co-morbidity
  • Resting systolic blood pressure \> 160 or \< 90 mmHg, diastolic blood pressure \> 95 or \< 50 mmHg
  • Clinically relevant ECG-abnormalities, prolonged QTc with \> 450 msec in males and \> 460 msec in females in particular
  • Presence of any relevant abnormality in the laboratory safety tests, especially low haemoglobin, increased liver enzymes
  • Positive serology for HBsAg, anti HBc and anti HCV
  • Positive HIV test
  • Positive alcohol or urine drug test on recruitment (and upon admission)
  • History of alcohol and/or drug abuse and/or daily use of \> 30 gr alcohol
  • Smoking more than 15 cigarettes/day or equivalent of other tobacco products
  • Use of prohibited medication
  • Suspicion or evidence that the subject is not trustworthy and reliable
  • Suspicion or evidence that the subject is not able to make a free consent or to understand the information in this regard
  • General - all females
  • Positive pregnancy test
  • Lactating
  • Not using appropriate contraception in pre-menopausal women (note: under the conditions of the present study, women using hormonal contraceptives will be informed that this method is not sufficient during the study and that further i.e. mechanical methods \[condom, diaphragm with spermacide gel\] should be used in addition).

Key Trial Info

Start Date :

June 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2006

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT00856752

Start Date

June 1 2006

End Date

August 1 2006

Last Update

March 6 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Dept. Clinical Pharmacology & Therapeutics, MHAPT "Zaritza Johanna" University Hospital

Sofia, Bulgaria, 1527